Jump to content

Olanzapine/samidorphan

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 16:02, 17 December 2017. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Olanzapine/samidorphan
Combination of
OlanzapineAtypical antipsychotic
SamidorphanOpioid modulator
Clinical data
Other namesALKS-3831
Legal status
Legal status

Olanzapine/samidorphan (developmental code name ALKS-3831) is a combination of the atypical antipsychotic olanzapine and the opioid modulator samidorphan which is under development by Alkermes, Plc. for the treatment of schizophrenia and bipolar mania.[1][2][3] As of June 2017, it is in phase III clinical trials for this indication.[1]

See also

References

  1. ^ a b http://adisinsight.springer.com/drugs/800037287
  2. ^ Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C (2016). "Improving Current Treatments for Schizophrenia". Drug Dev. Res. 77 (7): 357–367. doi:10.1002/ddr.21337. PMID 27633376.
  3. ^ Fellner C (2017). "New Schizophrenia Treatments Address Unmet Clinical Needs". P T. 42 (2): 130–134. PMC 5265239. PMID 28163559.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Olanzapine/samidorphan&oldid=815849150"